March 31 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH HEALTH ANNOUNCES FAVORABLE TOPLINE RESULTS FROM STUDY EVALUATING INVESTIGATIVE FORMULATION OF RIFAXIMIN SSD IR TO TREAT OVERT HEPATIC ENCEPHALOPATHY
* BAUSCH HEALTH COMPANIES INC - STUDY ARM EVALUATING 40 MG BID OF RIFAXIMIN SSD IR IN COMBINATION WITH STANDARD OF CARE THERAPY MET PRIMARY ENDPOINT
* BAUSCH HEALTH COMPANIES INC - RATES OF ADVERSE EVENTS WERE COMPARABLE ACROSS ALL TREATMENT ARMS OF STUDY